The Feasibility Study of Post-cataract Posterior Capsule Opacification (PCO) report was published on Thursday, 20 May 2021.
The Royal College of Ophthalmologists (RCOphth) recommends eye care centres monitor their own data to identify how their use of Intraocular Lenses (IOLs) affects the rate of a post-operative cataract surgical complication known as Posterior Capsular Opacification (PCO).
New analysis of over 600,000 cataract operations suggests that there is considerable potential to reduce PCO and reduce costs. Clinics could take steps to make better informed decisions on procurement, by improving data collection and moving to utilisation of Electronic Medical Records (EMR) across their whole eye service.
Analysis of the RCOphth National Ophthalmology Database (NOD) Cataract Audit dataset – which includes 601,084 cataract operations performed by 2,566 surgeons in 58 eye care centres – revealed vast variation in observed post-cataract PCO rates between different contributing centres and different IOL materials and designs, such as the higher observed PCO rate in IOLs with a hydrophilic component.
The analysis is published today in a report by RCOphth. The authors are Paul Donachie, John Buchan, and John Sparrow. This work was made possible with funding from Alcon, who are supporting the NOD programme.
PCO is a complication which can occur months or years after cataract surgery. PCO occurs when a cloudy layer of scar tissue forms behind the lens implant; this can cause blurred or hazy vision or glare from lights. PCO is estimated to occur in roughly one in five eyes that have cataract surgery and is usually treated by Yttrium Aluminium Garnet (YAG) laser surgery. Click here to continue reading
The Royal College of Ophthalmologists (RCOphth) is delighted to announce that the National Ophthalmology Database (NOD) Audit: Age-Related Macular Degeneration has now received funding for three years, enabling this important programme of long-term research and data gathering to begin. Age-Related Macular Degeneration (AMD) remains a leading cause of sight impairment despite new treatment options. It is estimated to affect 600,000 people in the UK, with 39,800 patients developing “wet” AMD each year.
The Macular Society kindly donated funding to lay the foundations of this new UK wide AMD audit programme. Additional funding from Novartis, Roche and Bayer will help implement and develop the new UK AMD audit over the next three years. The AMD audit will cover the whole of the UK and is led by a dedicated project delivery team and advisory group within NOD. The clinical lead is Martin McKibbin, leading AMD specialist, St. James’ University Hospital, Leeds.
Martin McKibbin explains “This new audit programme will help ensure that we get the best possible clinical outcomes and provide cost-effective patient care. Trusts and other providers commit a huge amount of effort and resource to meeting the growing demand for intra-vitreal injections for AMD and other retinal diseases. We all feel that we are providing high quality care and good clinical outcomes but have little opportunity to compare local outcomes with other sites. This new UK AMD audit will enable providers to compare treatment outcomes for “wet” or neovascular AMD, taking into account differences in baseline characteristics, and to identify the key clinical care processes. The UK AMD audit will bring opportunities to adopt best practice and, where necessary, to re-design local care pathways. Patients will be able to be reassured that every centre is providing high-quality care.”